Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Smith

Nurse Practitioner, Family Huntsville, AL Nurse Practitioner

NPI 1134548654 CMS profile 10953367

4606 Bellewood Dr, Huntsville, AL 35802

Open in the dashboard

General payments

$8,356

461 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Smith of Huntsville, AL is reported in the CMS Open Payments database as having received $8,356 across 461 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,857 100
2024 General $1,540 90
2023 General $1,781 90
2022 General $1,611 87
2021 General $1,568 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Smith
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jennifer Smith were reported at $1,857. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jennifer Smith Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,568 $124 $35–$379 $132
2022 $1,611 $141 $44–$430 $149
2023 $1,781 $154 $49–$476 $160
2024 $1,540 $165 $51–$504 $164
2025 $1,857 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,396 186 payments
  2. Amgen Inc. $1,610 102 payments
  3. UCB, Inc. $614 41 payments
  4. GlaxoSmithKline, LLC. $498 21 payments
  5. Janssen Biotech, Inc. $351 21 payments
  6. Novartis Pharmaceuticals Corporation $343 23 payments
  7. Mallinckrodt Hospital Products Inc. $334 9 payments
  8. AstraZeneca Pharmaceuticals LP $305 18 payments
  9. Arbor Pharmaceuticals, Inc. $141 2 payments
  10. Aurinia Pharma U.S., Inc. $122 5 payments
  11. Other $642 33 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,293 459 payments
  2. Education $63 2 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $2,659 151 payments
  2. Otezla $782 52 payments
  3. SKYRIZI $578 24 payments
  4. BENLYSTA $498 21 payments
  5. Cimzia $458 32 payments
  6. EVENITY $415 29 payments
  7. Enbrel Inflammation $380 25 payments
  8. Prolia $361 25 payments
  9. ACTHAR $334 9 payments
  10. Enbrel Inflammation $330 26 payments
  11. Other $3,257 172 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

2,069

Median for Nurse Practitioner: 389

Drug cost

$37,927

Median for Nurse Practitioner: $21,885

Branded share of claims

4.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 346 $8,926
Duloxetine Hcl Generic 245 $7,390
Gabapentin Generic 430 $6,372
Tizanidine Hcl Generic 263 $2,819
Celecoxib Generic 52 $2,172
Diclofenac Sodium Generic 59 $1,490
Amitriptyline Hcl Generic 84 $1,150
Cyclobenzaprine Hcl Generic 119 $1,026
Bupropion Xl Bupropion Hcl Brand 25 $732
Tramadol Hcl Er Tramadol Hcl Brand 16 $727

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$264,417

Of which drugs: $233,478

Medicare patients

283

Average age 73

Services billed

15,402

267 women, 16 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 67%
Depression 36%
Chronic kidney disease 28%
Diabetes 25%
Ischemic heart disease 23%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 126 9,004 $184,523
Injection, romosozumab-aqqg, 1 mg J3111 Office 21 5,671 $48,955

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $409
$409 — —
SKYRIZI
  • AbbVie, Inc. $248
$248 — —
Cimzia
  • UCB, Inc. $136
$136 — —
BENLYSTA
  • GlaxoSmithKline, LLC. $109
$109 — —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $89
$89 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

461 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record